

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive Ductal Carcinoma In Situ (DCIS)

Submission date 07/01/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 26/04/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/04/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-tamoxifen-or-anastrozole-in-postmenopausal-women-with-ductal-carcinoma-in-situ-of-the-breast>

Study website

<http://www.ibis-trials.org/>

Contact information

Type(s)

Scientific

Contact name

Prof Jack Cuzick

Contact details

Centre for Cancer Prevention
Wolfson Institute of Preventive Medicine
Charterhouse Square
London
United Kingdom
EC1M 6BQ
+44 (0)20 7882 3504
ibis@qmul.ac.uk

Type(s)

Scientific

Contact name

Miss Joanna Zahedi

Contact details

Project Manager/Data Manager

Barts CTU

Centre for Evaluation and Methods

Wolfson Institute of Population Health

Faculty of Medicine and Dentistry

Queen Mary University of London

London

United Kingdom

E1 4NS

-

j.zahedi@qmul.ac.uk

Additional identifiers

EudraCT/CTIS number

2004-003992-35

IRAS number**ClinicalTrials.gov number**

NCT00072462

Secondary identifying numbers

N/A

Study information

Scientific Title

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive, Ductal Carcinoma In Situ (DCIS)

Acronym

IBIS-II DCIS

Study objectives

Primary hypotheses:

1. To determine if anastrozole is at least as effective as tamoxifen in local control and prevention of contralateral disease in women with locally excised Estrogen Receptor (ER) or Progesterone Receptor (PgR) positive DCIS.
2. To compare side effect profiles of tamoxifen and anastrozole.

Secondary hypotheses:

1. To compare the effectiveness of tamoxifen and anastrozole according to the receptor status of the primary or recurrent cancer.
2. To examine the rate of breast cancer occurrence after cessation of tamoxifen or anastrozole.
3. To examine the effect of tamoxifen versus anastrozole on breast cancer mortality.

4. To examine the effect of tamoxifen and anastrozole on other cancers, cardiovascular disease, fracture rates, and non-breast cancer deaths.
5. To examine the tolerability and acceptability of side effects experienced by women on the study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study has been approved by the North West MREC (Multi-centre Research Ethics Committee) and local ethics committees (LREC).

Study design

Randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

No longer available

Health condition(s) or problem(s) studied

Breast cancer

Interventions

IBIS-II DCIS is a randomised double blind study investigating the use of anastrozole versus tamoxifen in women who have had a recent hormone receptor positive, locally excised DCIS lesion. There are two treatment groups:

Group A: tamoxifen 20 mg and anastrozole placebo

Group B. tamoxifen placebo and anastrozole 1 mg

Each patient will take the two tablets once a day for the next 5 years.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Tamoxifen, anastrozole

Primary outcome measure

All new and recurrent breast cancer

Secondary outcome measures

1. Breast cancer mortality
2. Thromboembolic events
3. Cardiovascular events
4. Osteoporosis
5. Other relevant side effects

Overall study start date

25/05/2003

Completion date

31/05/2021

Eligibility

Key inclusion criteria

Current inclusion criteria as of 23/02/2012:

1. All women must be postmenopausal and between the ages of 40 and 70 years.
Postmenopausal status is defined as meeting one or more of the following criteria:
 - 1.1. Over the age of 60 years
 - 1.2. Bilateral oophorectomy
 - 1.3. Aged 60 years or under with a uterus and amenorrhoea for at least 12 months
 - 1.4. Aged 60 years or under without a uterus and with Follicle-Stimulating Hormone (FSH) more than 30 IU/L
2. Women with locally excised Oestrogen Receptor (ER) positive DCIS excised within 6 months (ER or PR status must be greater than or equal to 5% positive cells)
3. A baseline bone mineral density scan within the last two years (dual-energy X-ray absorptiometry [DXA] either of hip, lumbar spine, forearm) and spinal X-ray will be required for all women
4. A fully informed signed consent form must have been obtained
5. Women who have had Lobular carcinoma in situ.
6. Women who have had Atypical hyperplasia in a benign lesion.
7. A bilateral mammogram must have been taken within the last year.
8. Women must be accessible for treatment and follow-up. Participants randomised in this trial must be treated and followed via a participating institution.

Previous inclusion criteria:

1. All women must be postmenopausal and between the ages of 40 and 70 years.
Postmenopausal status is defined as meeting one or more of the following criteria:
 - 1.1. Over the age of 60 years
 - 1.2. Bilateral oophorectomy
 - 1.3. Aged 60 years or under with a uterus and amenorrhoea for at least 12 months
 - 1.4. Aged 60 years or under without a uterus and with Follicle-Stimulating Hormone (FSH) more than 30 IU/L
2. Women with locally excised Oestrogen Receptor (ER) positive DCIS diagnosed within the last 6 months in which there are tumour free margins of at least 1 mm
3. A baseline bone mineral density scan within the last two years (dual-energy X-ray

absorptiometry [DXA] either of hip, lumbar spine, forearm) and spinal X-ray will be required for all women

4. A fully informed signed consent form must have been obtained

Participant type(s)

Patient

Age group

Adult

Lower age limit

40 Years

Upper age limit

70 Years

Sex

Female

Target number of participants

Target: 4000. Final: 2980.

Total final enrolment

2980

Key exclusion criteria

Current exclusion criteria as of 23/02/2012:

1. Have had (or are planning to have) their breast removed (a mastectomy)
2. Have had tamoxifen or raloxifene for more than 6 months in the last 5 years
3. Have had any other cancer in the last 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
4. Are taking medication to thin the blood
5. Have had a stroke
6. Have osteoporosis and fractures of the spine (if this applies, they may be able to take part - the trial doctor will assess each person on an individual basis)
7. Have any other serious medical condition
8. Have been taking part in any other clinical trial within the last 3 months
9. Any previous breast cancer at any age
10. Life expectancy of less than 10 years or any other medical condition that would significantly interfere with the ability to accept the chemopreventive treatment

Previous exclusion criteria:

1. Have had (or are planning to have) their breast removed (a mastectomy)
2. Have had tamoxifen, raloxifene or other Selective Estrogen Receptor Modulators (SERMs) for more than 3 months in the past
3. Have had any other cancer in the last 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
4. Are taking medication to thin the blood
5. Have had a stroke
6. Have osteoporosis and fractures of the spine (if this applies, they may be able to take part - the trial doctor will assess each person on an individual basis)

7. Have any other serious medical condition

8. Have been taking part in any other clinical trial within the last 3 months

Date of first enrolment

25/05/2003

Date of final enrolment

31/01/2012

Locations

Countries of recruitment

Australia

Austria

Belgium

Chile

England

Finland

France

Germany

Hungary

India

Ireland

Italy

Malta

New Zealand

Sweden

Switzerland

Türkiye

United Kingdom

Study participating centre

Wolfson Institute of Preventive Medicine
London
United Kingdom
EC1M 6BQ

Sponsor information

Organisation

Queen Mary University of London (UK)

Sponsor details

Dr Mays Jawad
Research & Development Governance Operations Manager
Joint Research Management Office
5 Walden Street
London
England
United Kingdom
E1 2EF
+44 (0)207 882 7275
sponsorsrep@bartshealth.nhs.uk

Sponsor type

University/education

Website

<http://www.jrmo.org.uk/>

ROR

<https://ror.org/026zzn846>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The initial results were published in 2014, the next major analysis was completed in 2020 and will be published in 2021. The final analysis for the purpose of the CSR will be uploaded within 12 months of the global EoT (31/05/2021). The long-term follow-up for this cohort is now conducted on a new protocol (IRAS 258590, REC 19/LO/0984, registration pending).

Intention to publish date**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	decision aid sub-study results	01/09/2008		Yes	No
Results article	results	27/02/2016		Yes	No
Results article	adherence results	01/02/2018		Yes	No